TruAlt Bioenergy Q3 FY26 Investor Presentation: Ethanol Capacity Expansion & CBG Growth
TruAlt Bioenergy's Q3 FY26 investor presentation details ethanol plant commissioning and increased utilization. The CBG segment shows strong margins, with plans for 24 new units via JVs. SAF project progresses with Honeywell UOP, seeking ₹150 crore funding. Consolidated Q3 revenue grew 70.20% QoQ to ₹720.72 crore.
The news includes details on operational capacity expansion, new project developments in CBG and SAF, and financial performance, which are material to investors and reflect the company's strategic direction and growth potential.
The announcement highlights significant operational achievements, including full commissioning of ethanol plants and strong performance in the CBG segment. Expansion plans and progress in the SAF sector indicate positive future outlook and growth opportunities.
TruAlt Bioenergy Limited has released its Investor Presentation for the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The company highlights the full commissioning of its grain-based integration capex, enabling its five ethanol plants to operate at over 95% utilization on operating days, with a monthly revenue run rate of approximately ₹350 to 400 crore in the ethanol segment. All ethanol plants are now fully operational, with no further expansion planned, targeting a monthly production of 5.5 to 6 crore liters.
The CBG segment has shown strong performance with an EBITDA Margin of 63% and a PAT Margin of 43% for the nine months ended December 31, 2025. The company plans to develop 24 greenfield CBG units over the next two to three years through joint ventures with Sumitomo Corporation and GAIL, with four new plants scheduled to commission by July 2026. The Union Budget 2026–27 announcements, including excise duty exemptions for biogas and CBG, are expected to significantly improve project economics.
In the Sustainable Aviation Fuel (SAF) segment, TruAlt Bioenergy has progressed with a technology licensing agreement with Honeywell UOP for a proposed 100 million litres per annum SAF facility in Andhra Pradesh. The company is in advanced stages of approvals for ₹150 crore of viability gap funding under the PM JI-VAN scheme. The retail network has seen seven outlets commissioned, with four more underway, and plans to scale to approximately 75 outlets in FY27.
Financially, for the nine months ended December 31, 2025, consolidated total income increased by 13.28% to ₹1187.05 crore, while PAT saw a marginal increase of 2.79% to ₹35.92 crore. For the third quarter of FY26, consolidated total income rose by 70.20% QoQ to ₹720.72 crore, with PAT at ₹66.02 crore.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.